Infliximab in ulcerative colitis

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 379-388

  Levin, Avi ^a   Shibolet, Oren ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anti TNF ; Antibody; Crohn's disease; Infliximab; Ulcerative colitis

Indexed keywords

EID: 77956414882     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Actis GC, Bruno M, Pinna-Pintor M, et al. 2002. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis, 34:631.
2. Ahmad T, Armuzzi A, Neville M, et al. 2003. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens, 62:527.
3. Argiles JM, Lopez-Soriano J, Busquets S, et al. 1997. Journey from cachexia to obesity by TNF. Faseb J, 11:743.
4. Armuzzi A, De Pascalis B, Lupascu A, et al. 2004. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci, 8:231.
5. Atreya R, Mudter J, Finotto S, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med, 6:583.
6. Baugh JA, Bucala R. 2001. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Devel, 4:635.
7. Baumgart DC, Sandborn WJ. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 369:1641.
8. Bazzoni F, Beutler B. 1996. The tumor necrosis factor ligand and receptor families. N Engl J Med, 334:1717.
9. Bermejo F, Lopez-Sanroman A, Hinojosa J, et al. 2004. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig, 96:94.
10. Binder V. 2004. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol, 18:463.
11. Bischoff SC, Lorentz A, Schwengberg S, et al. 1999. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut, 44:643.
12. Black RA, Rauch CT, Kozlosky CJ, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 385:729.
13. Bouma G, Crusius JB, Garcia-Gonzalez MA, et al. 1999. Genetic markers in clinically well defi ned patients with ulcerative colitis (UC). Clin Exp Immunol, 115:294
14. Bouma G, Strober W. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol, 3:521.
15. Bouma G, Xia B, Crusius JB, et al. 1996. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol, 103:391.
16. Braegger CP, Nicholls S, Murch SH, et al. 1992. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339:89.
17. Breese EJ, Michie CA, Nicholls SW, et al. 1994. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology, 106:1455.
18. Broome U, Lofberg R, Veress B, et al. 1995. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology, 22:1404.
19. Cao Q, Zhu Q, Wu ML, et al. 2006. Genetic susceptibility to ulcerative colitis in the Chinese Han ethnic population: association with TNF polymorphisms. Chin Med J (Engl), 119:1198.
20. Carter MJ, Lobo AJ, Travis SP. 2004. Guidelines for the management of inflammatory bowel disease in adults. Gut, 53, Suppl 5:V1.
21. Castro Fernandez M, Garcia Diaz E, Romero M, et al. 2003. [Treatment of steroid-refractory ulcerative colitis with infliximab]. Gastroenterol Hepatol, 26:54.
22. Cauwels A, Janssen B, Waeytens A, et al. 2003. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol, 4:387.
23. Chey WY, Hussain A, Ryan C, et al. 2001. Infliximab for refractory ulcerative colitis. Am J Gastroenterol, 96:2373.
24. Danese S, Semeraro S, Papa A, et al. 2005. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol, 11:7227.
25. D'Haens G, Lemmens L, Geboes K, et al. 2001. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology, 120:1323.
26. D'Haens G, Sandborn WJ, Feagan BG, et al. 2007. A review of activity indices and effi cacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology, 132:763.
27. Elliott MJ, Maini RN, Feldmann M, et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum, 36:1681.
28. Elson CO, Cong Y, McCracken VJ, et al. 2005. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev, 206:260.
29. Gisbert JP, Gonzalez-Lama Y, Mate J. 2007. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther, 25:19.
30. Gornet JM, Couve S, Hassani Z, et al. 2003. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther, 18:175.
31. Guy-Grand D, DiSanto JP, Henchoz P, et al. 1998. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol, 28:730.
32. Hanai H, Watanabe F, Yamada M, et al. 2004. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol, 99:1532.
33. Hanauer SB, Cohen RD, Becker RV 3rd, et al. 1998. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther, 20:1009.
34. Ina K, Itoh J, Fukushima K, et al. 1999. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol, 163:1081.
35. Iwakura Y, Ishigame H. 2006. The IL-23/IL-17 axis in inflammation. J Clin Invest, 116:1218.
36. Jacobsohn DA, Vogelsang GB. 2004. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des, 10:1195.
37. Järnerot G, Hertervig E, Friis-Liby I, et al. 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology, 128:1805.
38. Jung HC, Eckmann L, Yang SK, et al. 1995. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest, 95:55.
39. Knight DM, Trinh H, Le J, et al. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol, 30:1443.
40. Kohn A, Prantera C, Pera A, et al. 2002. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis, 34:626.
41. Komatsu M, Kobayashi D, Saito K, et al. 2001. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem, 47:1297.
42. Korzenik JR, Podolsky DK. 2006. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov, 5:197.
43. Kountouras J, Zavos C, Chatzopoulos D. 2005. Anti-tumor necrosis factor therapy for ulcerative colitis. Gastroenterology, 129:1138.
44. Lawson MM, Thomas AG, Akobeng AK. 2006. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 3:CD005112.
45. Lennard-Jones JE, Ritchie JK, Hilder W, et al. 1975. Assessment of severity in colitis: a preliminary study. Gut, 16:579.
46. Lichtenstein GR, Abreu MT, Cohen R, et al. 2006. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 130:935.
47. Lichtiger S, Present DH, Kornbluth A, et al. 1994. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med, 330:1841.
48. Ljung T, Karlen P, Schmidt D, et al. 2004. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut, 53:849.
49. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. 2000. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut, 46:336.
50. MacDonald TT, Hutchings P, Choy MY, et al. 1990. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol, 81:301.
51. Murch SH, Braegger CP, Walker-Smith JA, et al. 1993. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut, 34:1705.
52. Nilsen EM, Johansen FE, Jahnsen FL, et al. 1998. Cytokine profi les of cultured microvascular endothelial cells from the human intestine. Gut, 42:635.
53. Ochsenkuhn T, Sackmann M, Goke B. 2004. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol, 16:1167.
54. Old LJ. 1985. Tumor necrosis factor (TNF). Science, 230:630.
55. Papadakis KA, Targan SR. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med, 51:289.
56. Park H, Li Z, Yang XO, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6:1133.
57. Peppelenbosch MP, van Deventer SJ. 2004. T cell apoptosis and inflammatory bowel disease. Gut, 53:1556.
58. Plevy SE, Landers CJ, Prehn J, et al. 1997. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol, 159:6276.
59. Podolsky DK. 2002. Inflammatory bowel disease. N Engl J Med, 347:417.
60. Probert CS, Hearing SD, Schreiber S, et al. 2003. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut, 52:998.
61. Remicade package insert (Centocor-US), N., Rec 9/24/98.
62. Ruiz P, San Salvador P, Ortiz de Zarate J, et al. 2004. [Infliximab as treatment for a severe outbreak of ulcerative colitis]. Gastroenterol Hepatol, 27:430.
63. Rutgeerts P, Sandborn WJ, Feagan BG, et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 353:2462.
64. Sandborn WJ, Hanauer SB. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis, 5:119.
65. Sands BE, Kaplan GG. 2007. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol, 47:930.
66. Sands BE, Tremaine WJ, Sandborn WJ, et al. 2001. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis, 7:83.
67. Schroeder KW, Tremaine WJ, Ilstrup DM. 1987. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med, 317:1625.
68. Seo M, Okada M, Yao T, et al. 1992. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol, 87:971.
69. Shen C, de Hertogh G, Bullens DM, et al. 2007. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis, 13:308.
70. Shibolet, O, Regushevskaya E, Brezis M, et al. 2005. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane DatabaseSyst Rev:CD004277.
71. Siddiqui MA, Scott LJ. 2005. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs, 65:2179.
72. Soetikno RM, Lin OS, Heidenreich PA, et al. 2002. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc, 56:48.
73. Spoettl T, Hausmann M, Klebl F, et al. 2007. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis, 13:727.
74. Strober W, Fuss IJ, Blumberg RS. 2002. The immunology of mucosal models of inflammation. Annu Rev Immunol, 20:495.
75. Su C, Salzberg BA, Lewis JD, et al. 2002. Effi cacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol, 97:2577.
76. Tilg H, Moschen A, Kaser A. 2007. Mode of function of biological anti- TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther, 7:1051.
77. Truelove SC, Witts LJ. 1955. Cortisone in ulcerative colitis; fi nal report on a therapeutic trial. Br Med J, 2:1041.
78. Van Deventer SJ. 1997. Tumour necrosis factor and Crohn's disease. Gut, 40:443.
79. van Dullemen HM, van Deventer SJ, Hommes DW, et al. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology, 109:129.
80. van Heel DA, Udalova IA, De Silva AP, et al. 2002. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet, 11:1281.
81. Vassalli P. 1992. The pathophysiology of tumor necrosis factors. Annu Rev Immunol, 10:411.
82. Watkins PE, Warren BF, Stephens S, et al. 1997. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut, 40:628.
83. Wilson AG, de Vries N, Pociot F, et al. 1993. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med, 177:557.
84. Winther KV, Jess T, Langholz E, et al. 2003. Survival and cause-specifi c mortality in ulcerative colitis: follow-up of a population-based cohortin Copenhagen County. Gastroenterology, 125:1576.
85. Xavier RJ, Podolsky DK. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature, 448:427.